Dr. Reddy's joins with 7TM on research pact

India's Dr. Reddy's Laboratories is teaming up with 7TM on a drug discovery deal for metabolic disorders. Both companies agreed to collaborate on selecting new drug candidates, jointly advancing them through Phase IIa, when they can decide whether to license them out to another developer or take them on ahead as far as commercialization. The financial terms are being kept private.

"7TM has established a track record as one of the leading drug discovery companies focusing on GPCRs, and we are excited at the prospects of combining 7TM's capabilities with Dr. Reddy's to discover and develop innovative products," said Rajinder Kumar, Dr. Reddy's president.

- here's the release
- read the report from the Business Standard

Related Articles:
Dr. Reddy's make risky biogenerics move. Report
Dr Reddy's ready for new challenges? Report
Dr. Reddy's to buy Betapharm in $570M deal Report

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.